Greenphire’s Patient Experience Dataset establishes the industry’s first repository of global patient-level insights by phase, therapeutic area, and country, including average stipends (where permitted) and reimbursements by categorical expense, regulatory compliance guidelines, and more. This dataset delivers a comprehensive view into the patient journey, ultimately enabling sponsors and CROs to more accurately understand the burden associated with taking part in a clinical trial. In addition, this will allow industry stakeholders to better forecast and budget, predict and drive enrollment, streamline EC & IRB submissions in alignment with clinical trial agreements, and deliver the best patient experience.
“Greenphire has the industry’s largest patient experience dataset,” shares CEO Jim Murphy. “These data span a diverse set of therapeutic areas, phases, and countries across hundreds of customers and thousands of studies. Our Patient Experience Dataset gives sponsors the opportunity to access trusted data to transform their own study planning and budgeting with immediate access to average stipend and reimbursement costs by both cost category and percentile. Sponsors can even layer in basic assumptions, calculate estimations, and perform scenario analysis by leveraging our dataset in tandem with our budget development and cost benchmarking tool.”
Historically, the rate and method of patient reimbursements in clinical trials has been fairly inconsistent. To create more transparency regarding the drivers for patient compensation, the DIA has recently initiated a Patient Reimbursement Consortium focused on “examining and optimizing participant study reimbursement in clinical trials.” Greenphire was tapped as a Landmark Analysis Sponsor and working group member because of their years of experience and insights related to supporting patients.